FlandersBio on Twitter

Follow us on Twitter

Archive for July 2016 - News

Archive for July 2016 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

Genticel BUSINESS UPDATE - SECOND QUARTER 2016

29.07.2016

Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus (HPV), today announced its cash & cash equivalents and liquid investments position and its highlights from the second quarter of 2016. read more

Professor Francesco Di Virgilio joins Biosceptre Scientific Advisory Board

29.07.2016

Biosceptre announces today that Professor Francesco Di Virgilio, an international expert on the role of P2X7 in cancer, has joined the Scientific Advisory Board alongside its existing members, Sir Gregory Winter and Professor Terence Rabbitts. read more

Wanda Names Dr. Suzanne Steinbaum, Renowned Cardiologist and Women’s Heart Health Advocate, as Medical Director

28.07.2016

Dr. Steinbaum joins Wanda’s mission to create personalized health guidance and accountability using advanced predictive analytics, behavioural science, and mobile technologies. read more

VAX-ID by Novosanis to be used in Phase 1 vaccination trial by German biopharmaceutical company ImevaX

26.07.2016

Novosanis announced today their collaboration with ImevaX, a biopharmaceutical company based in Munich, Germany. ImevaX developed a vaccine against the pathogen Helicobacter pylori (H. pylori) that can cause chronic stomach sores and ulcers potentially leading to gastric cancer. Novosanis will supply the VAX-IDTM device that allows for a standardized and accurate injection of the vaccine for their clinical trials. read more

MDxHealth and Cerba HealthCare Announce Collaboration Agreement for SelectMDx Commercialization

25.07.2016

MDxHealth SA (Euronext: MDXH.BR) and Cerba HealthCare Belgium, announced today that they have signed a Collaboration Agreement to bring MDxHealth's SelectMDx(TM) for Prostate Cancer test to urology practitioners in France, Belgium and Luxembourg. read more

Novosanis signs agreement with the Mexican distributor of medical devices Distribuidora GAP

20.07.2016

Novosanis, a medical device company based in Belgium, announced today a new distribution partnership with Distribuidora GAP, short for Distribuidora Química y Hospitalaria GAP. As part of this agreement, Distribuidora GAP will sell the Novosanis’ Colli-PeeTM, a medical device suited for collection of first void urine, in Mexico. read more

Biocartis Group NV: Biocartis attracts EUR 55 million non-dilutive financing

20.07.2016

Biocartis Group NV ('Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that it has attracted a total of EUR 55m of non-dilutive financing, consisting of a EUR 40m bank and lease financing facility and a EUR 15m subordinated loan. The funds will be used to finance the expansion of Biocartis' manufacturing capacity for its IdyllaTM diagnostics tests, to refinance an existing loan of EUR 5m and to strengthen the company's financial position to continue to execute its strategic plan. read more

ABLYNX ANNOUNCES WARRANT EXERCISE

20.07.2016

Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 39,818 common shares have been issued by the Company in exchange for €160,489.39 as the result of the exercise of warrants. read more

EUROSCREEN opens US-IND for ESN364 on three Phase II trials

20.07.2016

Euroscreen announced today that it has opened an Investigational Drug Application (IND) with the U.S. Food and Drug Administration (FDA) to conduct pivotal efficacy and safety assessments to evaluate ESN364 in Phase II studies for the treatment of menopausal Hot Flashes, Poly Cystic Ovary Syndrome and Uterine Fibroids read more

Stem nu voor Qompium en help hen vooruit in de Aging20 wedstrijd!

20.07.2016

Tijdens de Happy Aging Day die plaatsvond op 16 juni 2016 in Bioville stemde u mogelijks mee voor de winnaar van de lokale pitch wedstrijd van Aging2.0, een wereldwijd innovatieplatform. Qompium behaalde tijdens deze lokale wedstrijd de meeste stemmen en won een ticket naar San Francisco. Met hun app voor screening van hartritmestoornissen, ging Qompium vervolgens door naar de volgende ronde in de wereldwijde zoektocht naar de beste startup. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top

Print